DNA
Ginkgo Bioworks Holdings, Inc. NYSE Listed Apr 19, 2021$8.94
-2.51%
vs $9.17
Mkt Cap $584.0M
52w Low $5.37
29.2% of range
52w High $17.58
50d MA $8.33
200d MA $9.38
P/E (TTM)
—
EV/EBITDA
—
P/B
1.0x
Debt/Equity
0.8x
ROE
-61.5%
P/FCF
-2.8x
RSI (14)
47.70
ATR (14)
$0.74
Beta
1.57
50d MA
$8.33
200d MA
$9.38
Avg Volume
1.3M
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
27 Drydock Avenue · Boston, MA 02210 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -1.21 | -1.39 | -14.8% | 10.32 | -16.2% | -13.5% | -2.9% | -3.8% | +3.0% | -8.6% | — |
| Feb 26, 2026 | AMC | -1.80 | -1.42 | +21.1% | 9.71 | -17.5% | -30.5% | +4.4% | -5.0% | -0.1% | +2.2% | — |
| Nov 6, 2025 | AMC | -1.24 | -1.45 | -16.9% | 11.30 | -8.9% | -20.8% | -2.0% | -3.5% | -1.2% | -4.3% | — |
| Aug 7, 2025 | AMC | -1.44 | -1.10 | +23.6% | 13.46 | +4.4% | -8.7% | -3.3% | -2.8% | +14.7% | -2.7% | — |
| May 6, 2025 | AMC | -1.23 | -1.58 | -28.5% | 6.45 | +5.9% | +14.7% | +6.4% | -1.4% | +7.1% | -2.3% | — |
| Feb 25, 2025 | AMC | -1.45 | -1.82 | -25.5% | 10.29 | -14.3% | -11.5% | -5.2% | -4.6% | -2.8% | +1.4% | — |
| Nov 12, 2024 | AMC | -2.40 | -1.08 | +55.0% | 8.39 | +8.3% | +2.5% | -15.0% | -12.9% | -0.6% | +1.9% | — |
| Aug 8, 2024 | AMC | -3.20 | -3.20 | +0.0% | 11.43 | +8.5% | -5.4% | -3.1% | +7.3% | -13.9% | +5.2% | — |
| May 9, 2024 | AMC | -3.20 | -3.20 | +0.0% | 36.80 | -13.4% | -17.3% | +10.5% | +2.6% | -2.8% | +0.0% | — |
| Feb 29, 2024 | AMC | -3.60 | -3.60 | +0.0% | 60.80 | -15.8% | -15.1% | -2.3% | -8.7% | +6.1% | -1.6% | — |
| Nov 8, 2023 | AMC | -3.60 | -3.60 | +0.0% | 59.60 | -6.7% | -15.4% | +1.6% | +0.0% | +12.5% | +8.3% | — |
| Aug 9, 2023 | AMC | -3.60 | -3.60 | +0.0% | 80.40 | -4.5% | -12.9% | +6.9% | -4.3% | -1.1% | -7.9% | — |
| May 10, 2023 | AMC | -3.60 | -3.20 | +11.1% | 54.00 | -7.4% | -1.5% | -7.5% | +7.3% | -5.3% | +1.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12 | BTIG | Maintains | Sell → Sell | — | $6.83 | $6.58 | -3.7% | -6.3% | +6.3% | -0.7% | +1.2% | -5.0% |
| Jan 8 | TD Cowen | Maintains | Buy → Buy | — | $9.61 | $9.33 | -2.9% | -5.7% | +2.0% | +3.5% | +0.6% | +2.4% |
| Aug 25 | BTIG | Maintains | Sell → Sell | — | $12.55 | $12.37 | -1.4% | -4.0% | +6.1% | -3.4% | -1.5% | +4.1% |
| Sep 20 | TD Cowen | Maintains | Buy → Buy | — | $8.31 | $8.31 | +0.0% | -3.6% | -2.2% | +3.1% | -3.8% | -0.8% |
| Aug 23 | BTIG | Maintains | Sell → Sell | — | $8.30 | $8.40 | +1.2% | -1.8% | -3.3% | -4.4% | -6.0% | +0.1% |
| Jul 9 | Goldman Sachs | Maintains | Sell → Sell | — | $13.62 | $13.60 | -0.1% | -9.4% | +5.3% | -1.5% | -10.1% | +0.7% |
| Jun 26 | BTIG | Maintains | Sell → Sell | — | $12.80 | $12.00 | -6.2% | -11.2% | +8.9% | +8.1% | -3.3% | +7.2% |
| May 15 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $34.51 | $35.92 | +4.1% | -2.8% | +0.0% | -4.0% | -4.9% | -4.5% |
| May 15 | BTIG | Downgrade | Neutral → Sell | — | $34.51 | $35.92 | +4.1% | -2.8% | +0.0% | -4.0% | -4.9% | -4.5% |
| May 10 | William Blair | Downgrade | Market Perform → Underperform | — | $36.80 | $31.88 | -13.4% | -17.3% | +10.5% | +2.6% | -2.8% | +0.0% |
| Mar 1 | TD Cowen | Maintains | Outperform → Outperform | — | $60.80 | $51.20 | -15.8% | -15.1% | -2.3% | -8.7% | +6.1% | -1.6% |
| Jan 23 | Goldman Sachs | Maintains | Sell → Sell | — | $49.20 | $50.40 | +2.4% | +3.3% | -2.4% | +1.6% | +2.4% | +4.7% |
| Jan 22 | Goldman Sachs | Maintains | Sell → Sell | — | $48.40 | $48.80 | +0.8% | +1.7% | +3.3% | -2.4% | +1.6% | +2.4% |
| Nov 15 | Raymond James | Downgrade | Outperform → Market Perform | — | $57.60 | $58.00 | +0.7% | +8.3% | -6.4% | +4.1% | +0.7% | -6.5% |
| Nov 14 | Raymond James | Downgrade | Outperform → Market Perform | — | $51.20 | $54.00 | +5.5% | +12.5% | +8.3% | -6.4% | +4.1% | +0.7% |
| Nov 9 | BTIG | Downgrade | Buy → Neutral | — | $59.60 | $55.60 | -6.7% | -15.4% | +1.6% | +0.0% | +12.5% | +8.3% |
| Jun 5 | Goldman Sachs | Maintains | Sell → Sell | — | $64.80 | $64.40 | -0.6% | +1.9% | +10.9% | -2.7% | -1.1% | +5.1% |
| Jun 2 | Goldman Sachs | Downgrade | Neutral → Sell | — | $67.20 | $65.20 | -3.0% | -3.6% | +1.9% | +10.9% | -2.7% | -1.1% |
| May 11 | William Blair | Downgrade | Outperform → Market Perform | — | $54.00 | $50.00 | -7.4% | -1.5% | -7.5% | +7.3% | -5.3% | +1.6% |
| Nov 29 | Berenberg | Maintains | Buy → Buy | — | $73.60 | $75.20 | +2.2% | +0.5% | +7.6% | -0.5% | +0.5% | -9.5% |
| Oct 4 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $125.60 | $131.60 | +4.8% | +12.1% | -6.0% | -2.4% | -4.3% | -6.5% |
| Aug 16 | BTIG | Maintains | Buy → Buy | — | $139.60 | $166.80 | +19.5% | +7.2% | -12.8% | -0.3% | -12.3% | -5.6% |
| Aug 16 | Raymond James | Maintains | Outperform → Outperform | — | $139.60 | $166.80 | +19.5% | +7.2% | -12.8% | -0.3% | -12.3% | -5.6% |
| Jun 16 | Jefferies | Maintains | Buy → Buy | — | $103.60 | $97.60 | -5.8% | -10.4% | +2.2% | +3.0% | +2.0% | +18.1% |
| May 18 | BofA Securities | Downgrade | Neutral → Underperform | — | $109.60 | $103.60 | -5.5% | -11.3% | +3.7% | +3.6% | +2.7% | -3.7% |
| Mar 2 | TD Cowen | Maintains | Outperform → Outperform | — | $171.60 | $177.20 | +3.3% | -0.9% | -9.2% | -11.1% | +0.6% | +0.9% |
| Feb 23 | Goldman Sachs | Maintains | Neutral → Neutral | — | $168.80 | $176.40 | +4.5% | +1.2% | +8.0% | -4.3% | +2.0% | -4.7% |
| Feb 1 | BofA Securities | Maintains | Neutral → Neutral | — | $239.20 | $241.60 | +1.0% | +4.0% | -1.3% | -6.5% | +5.2% | +1.0% |
| Jan 28 | BofA Securities | Maintains | Buy → Buy | — | $186.00 | $190.40 | +2.4% | +6.9% | +20.3% | +4.0% | -1.3% | -6.5% |
| Jan 7 | BTIG | Maintains | Buy → Buy | — | $276.00 | $281.20 | +1.9% | -1.2% | -1.6% | +1.8% | -8.3% | -1.9% |
| Oct 13 | Raymond James | Maintains | Outperform → Outperform | — | $433.20 | $444.80 | +2.7% | -5.4% | +13.5% | +2.4% | +3.4% | +20.2% |
| Oct 12 | William Blair | Maintains | Outperform → Outperform | — | $378.80 | $387.20 | +2.2% | +14.4% | -5.4% | +13.5% | +2.4% | +3.4% |
| Sep 20 | HSBC | Maintains | Buy → Buy | — | $487.20 | $482.00 | -1.1% | -8.8% | +5.3% | +1.5% | +3.6% | +2.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 22, 2026 | Coen Steven P.Off | See remarks | Sell | 307 | $8.33 | $3K | 50,704 | +0.23% | +2.08% |
8-K · 2.02
!! High
Ginkgo Bioworks Holdings, Inc. -- 8-K 2.02: Earnings Results
Ginkgo Bioworks reported first-quarter 2026 financial results, providing investors with updated performance metrics on revenue, expenses, and operational progress in synthetic biology.
May 7
8-K · 2.01
!!! Very High
Unknown — 8-K 2.01: Acquisition Completed
Ginkgo Bioworks completed a major acquisition, reshaping its balance sheet and operational scale as of year-end 2025; investors should monitor integration execution and synergy realization for stock impact.
Apr 7
8-K · 5.02
!!! Very High
Tivic Health Systems, Inc. -- 8-K 5.02: Executive Change
Tivic Health Systems appointed Michael K. Handley as Chief Executive Officer, signaling leadership transition that investors should monitor for strategic direction changes and operational impact.
Mar 4
8-K · 1.01
!! High
Ginkgo Bioworks Holdings, Inc. -- 8-K 1.01: Material Agreement
Ginkgo Bioworks acquired Tower Biosecurity through a stock purchase agreement, expanding its biosecurity and detection capabilities in synthetic biology applications.
Feb 27
8-K
Ginkgo Bioworks Holdings, Inc. -- 8-K Filing
Ginkgo Bioworks experienced a 24% year-over-year revenue decline in Q4 2025, falling to $33 million from $44 million, signaling potential challenges in executing its synthetic biology commercialization strategy.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Viking Global Investors | 3,577,128 | $22M | — | Mar 2026 |
| 2 | Morgan Stanley | 1,532,974 | $13M | Added | Dec 2025 |
| 3 | Vanguard Capital Management Llc | 1,914,428 | $12M | New | Mar 2026 |
| 4 | Forbes J M & Co Llp | 1,028,391 | $6M | Reduced | Mar 2026 |
| 5 | Prescott Group Capital Management, L.l.c. | 541,845 | $5M | New | Dec 2025 |
| 6 | Sb Investment Advisers (Uk) Ltd | 610,729 | $4M | New | Mar 2026 |
| 7 | Ubs Group Ag | 582,799 | $4M | Added | Mar 2026 |
| 8 | Vanguard Portfolio Management Llc | 565,652 | $3M | New | Mar 2026 |
| 9 | Millennium Management | 487,957 | $3M | Added | Mar 2026 |
| 10 | Bank Of America Corp /de/ | 476,913 | $3M | Reduced | Mar 2026 |
| 11 | Tudor Investment Corp | 464,663 | $3M | New | Mar 2026 |
| 12 | Northern Trust Corp | 334,178 | $2M | Added | Mar 2026 |
| 13 | Aqr Capital Management Llc | 294,788 | $2M | Added | Mar 2026 |
| 14 | Jane Street Group, Llc | 181,755 | $2M | Added | Dec 2025 |
| 15 | Invesco Ltd. | 234,808 | $1M | Reduced | Mar 2026 |
| 16 | Nuveen, Llc | 181,749 | $1M | Added | Mar 2026 |
| 17 | Bnp Paribas Financial Markets | 172,716 | $1M | Reduced | Mar 2026 |
| 18 | Universal- Beteiligungs- Und Servicegesellschaft Mbh | 140,000 | $858K | — | Mar 2026 |
| 19 | Bank Of New York Mellon Corp | 123,959 | $760K | Added | Mar 2026 |
| 20 | Man Group Plc | 109,117 | $669K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$584.0M
Enterprise Value
$503.0M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.03x
P/B
0.97x
P/S
3.51x
P/FCF
-2.85x
EV/EBITDA
—
Shares Out
55.5M
Financials (TTM)
Revenue
$141.3M
Net Income
-$304.4M
EBITDA
-$210.9M
Free Cash Flow
-$178.7M
Op Cash Flow
-$171.1M
EPS Basic
$-5.64
EPS Diluted
$-5.37
EPS Forward
$-4.43
Gross Margin
75.0%
Op Margin
-210.7%
Net Margin
-215.4%
Balance Sheet
Total Assets
$1.12B
Total Liab.
$611.1M
Total Equity
$508.6M
Cash
$422.6M
LT Debt
$417.1M
Book Value/Sh
$9.17
Debt/Equity
0.82x
Current Ratio
4.92
Quick Ratio
4.92
Returns & Growth
ROE
-61.5%
ROA
-27.9%
ROIC
-30.7%
Rev Growth YoY
-25.1%
EPS Growth YoY
+46.5%
Price Returns
2W
+19.4%
1M
+10.8%
3M
+38.8%
6M
+1.0%
12M
+34.8%
Technicals
52W High
$17.58
52W Low
$5.37
50d MA
$8.33
200d MA
$9.38
RSI (14)
47.70
ATR (14)
$0.74
Beta
1.57
Avg Volume
1.3M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$7.84
High
$12.00
Low
$4.35
Median
$7.50
Data updated apr 25, 2026 5:29am
· Source: financialmodelingprep.com